Rheumatoid arthritis patients with higher paraoxonase levels have lower MACE, cancer rates

Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.
“Paraoxonase-1 (PON1) is a major high-density lipoprotein cholesterol (HDL-c)-associated enzyme synthesized mainly in the liver and secreted into the blood, where it associates predominantly with HDL-c,” Christina Charles-Schoeman, MD, MS, of the University of California Los Angeles, and colleagues wrote. “PON1 is considered to be

Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.
“Paraoxonase-1 (PON1) is a major high-density lipoprotein cholesterol (HDL-c)-associated enzyme synthesized mainly in the liver and secreted into the blood, where it associates predominantly with HDL-c,” Christina Charles-Schoeman, MD, MS, of the University of California Los Angeles, and colleagues wrote. “PON1 is considered to be